血栓模块素开关信号和蛋白酶激活受体 1 分裂 血栓的特异性
Indranil Biswas1, Hemant Giri1,2, Sumith R Panicker1,3
1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation (I.B., H.G., S.R.P., A.R.R.).
Arteriosclerosis, thrombosis, and vascular biology
|January 4, 2024
概括
血栓模块素结合决定了血栓激素的结合.
科学领域:
- 内皮细胞生物学 内皮细胞生物学
- 接收器信号通路是指接收器信号通路.
- 蛋白酶激活受体的受体.
背景情况:
- 蛋白酶激活受体1 (PAR1) 通过血栓素和激活蛋白C (APC) 分裂导致矛盾的内皮细胞反应.
- 内皮蛋白C受体 (EPCR) 对于APC介导的细胞保护性PAR1信号传递至关重要.
- 研究了血栓模块素在调节血栓的PAR1信号特异性的作用.
研究的目的:
- 阐明血栓模块素在确定PAR1信号的特异性中的作用.
- 了解血栓模块素如何影响血栓激素诱导的裂变和下游信号通路.
- 为了比较在核心受体的存在下,PAR1通过血栓素和APC分裂的信号结果.
主要方法:
- 使用CRISPR/Cas9.9生成一个PAR1淘汰内皮细胞系.
- 用PAR1突变体对淘汰细胞进行转导,以研究分裂部位的特异性.
- 感染HEK293细胞与PAR1裂变记者结构.
主要成果:
- 血栓模块素结合指导血栓素在Arg46上切割PAR1,通过β-arrestin-2启动细胞保护信号传递.
- 血-血模块复合体可以比APC更快地切割Arg46.
- 血栓模块素招募β-arrestin,使得Arg41被血栓分裂也可以通过β-arrestin-1信号进行细胞保护.
结论:
- 由血栓模块素和EPCR发出的核心受体信号决定了血素和APC的独特的PAR1裂变和信号特异性.
- 血栓模块素通过偏向的β-arrestin招募促进血栓因子的细胞保护信号传递.
- 了解这些特点对于治疗内皮功能障碍的有针对性的治疗干预至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
702
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
702
Intracellular Signaling Affects Focal Adhesions
2.7K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.7K
Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
Extrinsic and Intrinsic Pathways of Hemostasis
7.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.8K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


